Targretin
bexarotene · H.A.C. Pharma
AUTHORISED IN THE EUWhat Targretin is used for
Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Targretin
- Active substance
- bexarotene
- Disease area
- Lymphoma, T-Cell, Cutaneous
- Medicine group
- Antineoplastic agents
- ATC code
- L01XF03
- Marketing authorisation holder
- H.A.C. Pharma
- Authorised in the EU since
- 2001
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Targretin used for?
Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.
What is the active substance in Targretin?
Targretin contains bexarotene.
Who makes Targretin?
The EU marketing authorisation holder is H.A.C. Pharma.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU